Literature DB >> 20950210

Low prevalence of hereditary hemochromatosis in multiethnic populations in Northern Norway.

Ann R Broderstad1, Tone Smith-Sivertsen, Inger Marie Dahl, Ole Christian Ingebretsen, Eiliv Lund.   

Abstract

OBJECTIVE: Hereditary hemochromatosis has an autosomal recessive inheritance. The C282Y homozygosity is the most common genetic mutation in persons of Northern European descent. A screen of two multiethnic populations in Northern Norway was performed to investigate whether the prevalence of hereditary hemochromatosis was consistent with previous results in Northern Europe.
MATERIAL AND METHODS: Participants in two population-based studies in Northern Norway were analyzed for serum ferritin (s-ferritin) and transferrin saturation. Participants with s-ferritin or transferrin saturation above the reference limits in two separate blood samples were tested for three different HFE mutations, namely C282Y, H63D and S65.
RESULTS: The estimated prevalence of the C282Y/C282Y mutation in the two municipalities studied was lower than in comparable studies in Norway. The prevalence was the lowest in the Sør-Varanger population (men 0.19% and women 0.22%), which also had the highest proportion of individuals with Sami and Kven affiliation. In Tromsø, the prevalence was consistent with previous results in Norway.
CONCLUSIONS: The prevalence of hereditary hemochromatosis is lower in multiethnic populations in Northern Norway than in previous studies from other parts of Norway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950210     DOI: 10.3109/00365521.2010.525713

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  1 in total

1.  Polymorphisms related to the serum 25-hydroxyvitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromsø Study.

Authors:  Rolf Jorde; Henrik Schirmer; Tom Wilsgaard; Ragnar Martin Joakimsen; Ellisiv Bøgeberg Mathiesen; Inger Njølstad; Maja-Lisa Løchen; Yngve Figenschau; Jens Petter Berg; Johan Svartberg; Guri Grimnes
Journal:  PLoS One       Date:  2012-05-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.